In vitro activity of piperacillin/tazobactam against 615 Pseudomonas aeruginosa strains isolated in intensive care units

Chemotherapy

Volumn 44, Issue 5, 1998, Pages 305-312

  Bonfiglio, Giovanni ^a   Laksai, Younes ^a   Franceschini, Nicola ^b   Perilli, Mariagrazia ^b   Segatore, Bernadetta ^b   Bianchi, Ciro ^c   Stefani, Stefania ^a   Amicosante, Gianfranco ^b   Nicoletti, Giuseppe ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c Wyeth Lederle   (Italy)

Author keywords

Antibiotic resistance; Intensive care unit; Piperacillin tazobactam; Pseudomonas aeruginosa; lactamase inhibitor

Indexed keywords

AMIKACIN; BETA LACTAMASE; CARBENICILLIN; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TIMENTIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; HYDROLYSIS; INTENSIVE CARE; ISOELECTRIC FOCUSING; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

EID: 0031812659     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007127     Document Type: Article

References (25)

1. Jarvis WR, Martone WJ: Predominant pathogens in hospital infections. J Antimicrob Chemother 1992;29(suppl A):19-24.
2. Trilla A: Epidemiology of nosocomial infections in adult intensive care units. Intensive Care Med 1994;20 (suppl 3):S1-S4.
3. Jalier V, Fosse T, Philippon A, ICU Study Group: Antibiotic susceptibility in aerobic bacilli isolated in intensive care units in 39 French teaching hospitals (ICU study). Intensive Care Med 1996;22:1057-1065.
4. Wolff M, Brun-Buisson C, Lode H, Mathai D, Lewi D, Pittet D: The changing epidemiology of severe infections in the ICU. Clin Microbiol Infect 1997;3(suppl 1):S36-S47.
5. Stefani S, Bonfiglio G, Urzì S, Nicoletti G: Susceptibility survey of piperacillin/tazobactam and some β-lactam comparators in Italy. Drug Exp Clin Res, in press.
6. Bush K: Characterisation of β-lactamases. Classification of β-lactamases: Group 1, 2a, 2b, and 2b′. Classification of β-lactamases: Groups 2c, 2d, 2e, 3 and 4. Antimicrob Agents Chemother 1989;33: 259-263, 264-270, 272-276.
7. Poole K, Krebes K, McNally C, Neshat S: Multiple antibiotic resistance in Pseudomonas aeruginosa: Evidence for involvement of an efflux operon. J Bacteriol 1993;175:7363-7372.
8. Li X-Z, Ma S, Livermore DM, Nikaido H: Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: Active efflux as a contributing factor to β-lactam resistance. Antimicrob Agents Chemother 1994;38:1742-1752.
9. Livermore DM: Mechanisms of resistance to β-lactam antibiotics. Scand J Infect Dis Suppl 1991;78:7-16.
10. Livermore DM, Chen HY, Bonfiglio G: Beta-lactamase-mediated resistance and its reversal by tazobactam and other inhibitors. Fortschr Antimikrob Antineoplast Chemother 1992;11:379-388.
11. Bonfiglio G, Carciotto V, Russo G, Stefani S, Schito GC, Debbia E, Nicoletti G: Antibiotic resistance in Pseudomonas aeruginosa: An Italian survey. J Antimicrob Chemother 1998;41:307-310.
12. Williams RJ, Livermore DM, Lindridge MA, Said AA, Williams JD: Mechanisms of β-lactam resistance in British isolates of Pseudomonas aeruginosa. J Med Microbiol 1984; 17:283-293.
13. National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria which grow aerobically, ed 4, approved standard. Wayne, 1997, NCCLS document M7-A4.
14. Akova M, Bonfiglio G, Livermore DM: Susceptibility to β-lactam antibiotics of mutant strains of Xanthomonas maltophilia with high-and low-level constitutive expression of L-1 and L-2 β-lactamases. J Med Microbiol 1991;35:208-213.
15. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
16. Spencer CR, Bauernfeind A, Garcia-Rodriguez J, Jarlier V, Pfaller M, Tumidge J, Voss A: Surveillance of the current resistance of nosocomial pathogens to antibacterials. Clin Microbiol Infect 1997;3(suppl 1):S21-S35.
17. Buscher KH, Cullmann W, Dick W, Opferkuch W: Imipenem resistance in Pseudomonas aeruginosa resulting from diminished expression of an outer membrane protein. Antimicrob Agents Chemother 1986;31: 703-708.
18. Trias J, Nikaido H: Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1990;34:147-151.
19. Chen HY, Bonfiglio G, Alen M, Piper D, Edwardson T, McVey D, Livermore DM: Multicentre survey of the comparative in-vitro activity of piperacillin/tazobactam against bacteria from hospitalised patients in the British Isles. J Antimicrob Chemother 1993;32:247-266.
20. Verbist L, Verhaegen J, Wouters CH, Vandenhoven G, and a multicentre study group: Comparative activity of piperacillin/tazobactam against, 5,625 isolates from hospitalised patients. J Antimicrob Chemother 1996;37:285-293.
21. Declerq P, Lievens P: In vitro evaluation of the efficacy of meropenem, cefepime and cefpirome towards Pseudomonas aeruginosa in relationship with more established antibiotics (abstract 5327). 20th International Congress of Chemotherapy, Sydney, 1997, p 209.
22. Chattopadhayay B, Teli J: Comparative in-vitro activity of eight antibacterial agents against clinical isolates of Pseudomonas aeruginosa (abstract 2335). 20th International Congress of Chemotherapy, Sydney, 1997, p 48.
23. Pierson CL, Friedman B: Comparison of susceptibility to β-lactam antimicrobial agents among bacteria isolated from intensive care units. Diagn Microbiol Infect Dis 1992;15: 19S-30S.
24. Neu HC: The crisis in antibiotic resistance. Science 1992;257:1064-1073.
25. Stratton CW, Ratner H, Johnson PE, Schaffner W: Focused microbiologic surveillance by specific hospital unit as a sensitive means of defining antimicrobial resistance problems. Diagn Microbiol Infect Dis 1992;15:3S-10S.